RNDr. Pavel Krejčí, Ph.D.
Head of the research group, Pavel Krejčí Research Group
office: bldg. A19/231a
Kamenice 753/5
625 00 Brno
phone: | +420 549 49 5395 |
---|---|
e‑mail: |
social and academic networks: |
---|
Total number of publications: 128
2011
-
The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting insuppression of human myeloma cell growth and survival.
Leukemia, year: 2011, volume: 25, edition: 3, DOI
-
Wnt/PCP pathway regulates B-cell migration in chronic lymphocytic leukemia
Year: 2011, type: Conference abstract
2010
-
Breast cancer-specific mutations in CK1epsilon inhibit Wnt/beta-catenin and activate the Wnt/Rac1/JNK and NFAT pathways to decrease cell adhesion and promote cell migration.
Breast Cancer Research, year: 2010, volume: 2010, edition: 12/3, DOI
-
FGFR3 signaling induces a reversible senescence phenotype in chondrocytes similar to oncogene-induced premature senescence
Bone, year: 2010, volume: neuveden, edition: 47
-
Negative regulation of Wnt signaling mediated by CK1- phosphorylated Dishevelled via Ror2
FASEB JOURNAL, year: 2010, volume: 24, edition: 7, DOI
-
Nf449 is a novel inhibitor of fibroblast growth factor receptor 3 (fgfr3) signaling active in chondrocytes and multiple myeloma cells
J. Biol. Chem., year: 2010, volume: 285, edition: 27, DOI
2009
-
FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway
Human Molecular Genetics, year: 2009, volume: 18, edition: 2
-
Fibroblast growth factor inhibits interferon gama-STAT1 and interleukin 6-STAT3 signaling in chondrocytes
Cellular Signalling, year: 2009, volume: 21, edition: 1, DOI
-
High molecular weight FGF2: the biology of a nuclear growth factor
Cellular and molecular life sciences : CMLS, year: 2009, volume: 66, edition: 2, DOI
-
Molecular pathology of the fibroblast growth factor family.
Human Mutation, year: 2009, volume: 30, edition: 9, DOI